JPWO2020157362A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157362A5 JPWO2020157362A5 JP2021532911A JP2021532911A JPWO2020157362A5 JP WO2020157362 A5 JPWO2020157362 A5 JP WO2020157362A5 JP 2021532911 A JP2021532911 A JP 2021532911A JP 2021532911 A JP2021532911 A JP 2021532911A JP WO2020157362 A5 JPWO2020157362 A5 JP WO2020157362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- administered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024158993A JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382061.0 | 2019-01-30 | ||
| EP19382061 | 2019-01-30 | ||
| US201962913259P | 2019-10-10 | 2019-10-10 | |
| US62/913,259 | 2019-10-10 | ||
| PCT/ES2020/070070 WO2020157362A1 (en) | 2019-01-30 | 2020-01-30 | Inositol phosphate compounds for use in increasing tissular perfusion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Division JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521119A JP2022521119A (ja) | 2022-04-06 |
| JP2022521119A5 JP2022521119A5 (https=) | 2022-09-14 |
| JPWO2020157362A5 true JPWO2020157362A5 (https=) | 2022-09-14 |
Family
ID=69770927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532911A Pending JP2022521119A (ja) | 2019-01-30 | 2020-01-30 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220000889A1 (https=) |
| EP (1) | EP3917535A1 (https=) |
| JP (2) | JP2022521119A (https=) |
| KR (1) | KR20210148078A (https=) |
| CN (1) | CN113365636A (https=) |
| AU (1) | AU2020213713B2 (https=) |
| BR (1) | BR112021014897A2 (https=) |
| CA (1) | CA3130735A1 (https=) |
| IL (1) | IL285084A (https=) |
| MX (1) | MX2021008966A (https=) |
| WO (1) | WO2020157362A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018445164B2 (en) | 2018-10-11 | 2025-05-29 | Vifor (International) Ltd. | Inositol phosphates for the treatment of ectopic calcification |
| MX2023005931A (es) * | 2020-11-20 | 2023-08-03 | Vifor Int Ag | Analogos de hexakisfosfato de inositol para el tratamiento de enfermedades renales asociadas con la calcificacion. |
| WO2024047037A1 (en) | 2022-08-30 | 2024-03-07 | ETH Zürich | Compositions for parenteral sustained release delivery of hydrophilic drugs |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| ATE173159T1 (de) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO2001013933A2 (en) * | 1999-08-25 | 2001-03-01 | Gmp Companies, Inc. | Agents for the enhanced oxygen delivery in mammals |
| AU7995600A (en) * | 1999-10-05 | 2001-05-10 | Theramed, Inc. | Compositions and methods for the incorporation of chemical substances into cells |
| CA2389236A1 (en) | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US20020142995A1 (en) * | 2000-08-01 | 2002-10-03 | Nicolau Yves Claude | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| WO2002010177A1 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| JP3678144B2 (ja) | 2000-12-22 | 2005-08-03 | ウシオ電機株式会社 | フィルム回路基板の周辺露光装置 |
| JP2004532259A (ja) | 2001-05-29 | 2004-10-21 | デポメッド ディベロップメント リミティド | 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法 |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| CN105949234B (zh) | 2011-09-29 | 2018-07-10 | 苏黎世联邦理工学院 | 用于治疗艰难梭菌感染的药物化合物 |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| ES2495666B1 (es) * | 2013-03-15 | 2015-08-10 | Laboratoris Sanifit, S.L. | Uso de derivados con enlaces c-o-p en pacientes con fallo renal |
| EA037572B1 (ru) * | 2015-12-11 | 2021-04-15 | Этх Цюрих | Производные инозитола для применения в патологической кристаллизации |
| DK3386994T3 (da) | 2015-12-11 | 2020-01-13 | Eth Zuerich | 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion |
-
2020
- 2020-01-30 CN CN202080010978.XA patent/CN113365636A/zh active Pending
- 2020-01-30 AU AU2020213713A patent/AU2020213713B2/en active Active
- 2020-01-30 MX MX2021008966A patent/MX2021008966A/es unknown
- 2020-01-30 KR KR1020217023799A patent/KR20210148078A/ko active Pending
- 2020-01-30 BR BR112021014897-3A patent/BR112021014897A2/pt unknown
- 2020-01-30 WO PCT/ES2020/070070 patent/WO2020157362A1/en not_active Ceased
- 2020-01-30 JP JP2021532911A patent/JP2022521119A/ja active Pending
- 2020-01-30 EP EP20709635.5A patent/EP3917535A1/en active Pending
- 2020-01-30 CA CA3130735A patent/CA3130735A1/en active Pending
-
2021
- 2021-07-20 US US17/381,052 patent/US20220000889A1/en not_active Abandoned
- 2021-07-22 IL IL285084A patent/IL285084A/en unknown
-
2023
- 2023-04-11 US US18/298,811 patent/US20230248749A1/en not_active Abandoned
-
2024
- 2024-09-13 JP JP2024158993A patent/JP2024175025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (https=) | ||
| JP2012503661A5 (https=) | ||
| JP2010514797A5 (https=) | ||
| JP2010530881A5 (https=) | ||
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JP2022521119A5 (https=) | ||
| US20080319038A1 (en) | Preventative or therapeutic agent for acute renal failure | |
| JP2021102643A5 (https=) | ||
| JP2020517736A (ja) | 腎臓損傷の治療及び予防 | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| JPWO2020117987A5 (https=) | ||
| JP4011114B2 (ja) | 脳浮腫抑制剤 | |
| JPWO2020157362A5 (https=) | ||
| US3868451A (en) | Adenosine-5{40 -esters in treating angina pectoris | |
| CN115813920A (zh) | 1,2,4三唑并4,3-b哒嗪衍生物在制备治疗慢性肾病的药物中的应用 | |
| JPH1036365A5 (https=) | ||
| RU2021125195A (ru) | Соединения инозитолфосфата для применения для увеличения тканевой перфузии | |
| JPWO2021094331A5 (https=) | ||
| JPS63104960A (ja) | α−［（フェニルメトキシ）メチル］ピリジンアルカノール誘導体 | |
| US4963577A (en) | Use of the thiazole derivative tiprotimod for the preparation of an agent for the therapy of virus infections | |
| JP4078397B2 (ja) | 下痢の予防及び治療剤 | |
| JPWO2023052363A5 (https=) | ||
| CN1354666A (zh) | 低毒的抗炎抗渗出药物组合物 | |
| EP0717625B1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| RU2259827C2 (ru) | Лечение или предупреждение гипотензии и шока |